Pernix Therapeutics Holdings (NASDAQ:PTX) Earns Daily Media Impact Score of 0.19
News headlines about Pernix Therapeutics Holdings (NASDAQ:PTX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pernix Therapeutics Holdings earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 47.0217900113735 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- NASDAQ 20 Leading Losers as of Friday, Aug. 11 (fxpips.com)
- Pernix Therapeutics Holdings, Inc. (companyspotlight.com)
- Contrasting Adamis Pharmaceuticals Corporation (ADMP) & Pernix Therapeutics Holdings (NASDAQ:PTX) (americanbankingnews.com)
- ETFs with exposure to Pernix Therapeutics Holdings, Inc. : August 8, 2017 (finance.yahoo.com)
- Stock recommendation to Hold: Pernix Therapeutics Holdings, Inc. (PTX) – Street Observer (press release) (streetobserver.com)
Separately, ValuEngine downgraded shares of Pernix Therapeutics Holdings from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 8th.
Pernix Therapeutics Holdings (PTX) opened at 2.51 on Tuesday. The firm’s 50-day moving average is $3.63 and its 200-day moving average is $3.82. The company’s market capitalization is $27.90 million. Pernix Therapeutics Holdings has a 1-year low of $1.83 and a 1-year high of $9.20.
Pernix Therapeutics Holdings (NASDAQ:PTX) last announced its earnings results on Thursday, July 27th. The specialty pharmaceutical company reported ($2.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.40) by $2.24. The company had revenue of $34.32 million for the quarter. Equities research analysts predict that Pernix Therapeutics Holdings will post ($3.70) EPS for the current year.
WARNING: “Pernix Therapeutics Holdings (NASDAQ:PTX) Earns Daily Media Impact Score of 0.19” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/15/pernix-therapeutics-holdings-nasdaqptx-earns-daily-media-impact-score-of-0-19.html.
About Pernix Therapeutics Holdings
Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Receive News & Stock Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related stocks with our FREE daily email newsletter.